Holen Sie sich die Stockscreener-App
4.62
4.05%
0.18
Handel nachbörslich:
4.44
-0.18
-3.90%
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Financial Metrics Check: Dogwood Therapeutics Inc. (DWTX)’s Ratios for Trailing Twelve Months - The Dwinnex
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Dogwood Therapeutics (DWTX) Stock Chart and Price History 2024 - MarketBeat
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.03% - Investing.com India
Virios Therapeutics shares target raised on Wex merger news - Investing.com
New obesity treatment has this tiny co soaring 💃 - RagingBull
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - Marketscreener.com
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics - MSN
Virios Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Conjoint Inc. Enters into the Loan Agreement with the Virios Therapeutics, Inc - Marketscreener.com
Virios Therapeutics announces strategic merger and financing By Investing.com - Investing.com UK
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - Yahoo Finance
Virios Therapeutics Announces Second Quarter 2024 Financial Results - Marketscreener.com
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Capital Bancorp (CBNK) to Buy Integrated Financial for $66M - Yahoo Finance
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - Marketscreener.com
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement - Marketscreener.com
Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023 - Marketscreener.com
Virios Therapeutics Announces Halt to At-The-Market Offering Sales - Marketscreener.com
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study - Marketscreener.com
Virios Therapeutics : Letter from Nasdaq, dated May 24, 2023 (furnished herewith)Form 8-K - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Other Events (form 8-K) - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - Marketscreener.com
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 - Marketscreener.com
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program - Marketscreener.com
Transcript : Virios Therapeutics, Inc., Q3 2022 Earnings Call, Nov 14, 2022 - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022 - Marketscreener.com
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference - Marketscreener.com
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateForm 8-K - Marketscreener.com
Virios Therapeutics : Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress - Marketscreener.com
Virios Therapeutics : Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW) - Marketscreener.com
Virios Therapeutics Announces Unaudited Earnings Results for the Quarter and Year Ended December 31, 2020 - Marketscreener.com
Virios Therapeutics LLC : to Present at the H.C. Wainwright Virtual BioConnect Conference - Marketscreener.com
Innovative Med Concepts Names Rick Burch as President - Marketscreener.com
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):